{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:30:39Z","timestamp":1789446639644,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021170","name":"Brain Tumour Research","doi-asserted-by":"publisher","award":["Hanemann"],"award-info":[{"award-number":["Hanemann"]}],"id":[{"id":"10.13039\/501100021170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Meningiomas are the most common primary intracranial tumours, with clinical behaviours ranging from benign to highly aggressive forms. The World Health Organisation classifies meningiomas into various grades, guiding prognosis and treatment. While surgery is effective for low-grade meningiomas, certain grade 1 tumours, as well as grade 2, 3, and recurrent cases are more aggressive and require new therapeutic approaches. Immunotherapy shows promise, with early-stage clinical trials demonstrating encouraging results. The tumour microenvironment (TME), particularly tumour-associated macrophages (TAMs), plays a pivotal role in tumour progression. TAMs influence tumour growth, metastasis, and immune evasion. However, their role in meningiomas, especially in relation to genomic mutations, remains poorly understood. Understanding how genetic alterations affect the TME is critical for developing targeted immunotherapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study employed multiplex immunohistochemistry and bulk RNA sequencing to explore immune infiltration in genetically stratified meningioma tissues and matched three-dimensional (3D) spheroid models. We compared immune cell populations across parental tissues, two-dimensional (2D) monolayer cultures, and 3D spheroid models. In addition, co-culture experiments were conducted, introducing M2-polarised macrophages derived from peripheral blood mononuclear cells to study the interactions between immune cells and tumour cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our findings revealed significant differences in the immune infiltration patterns associated with specific genotypes and methylation classes, especially M2-like TAMs. Notably, the 3D spheroid models more closely replicated the TME observed in parental tissues compared to traditional 2D monolayer cultures, offering a superior platform for immune infiltration studies. Furthermore, co-culture experiments demonstrated that M2-polarised macrophages could effectively infiltrate tumour cells, promote tumour cell proliferation while inhibiting invasion, suggesting IL-6-mediated signalling in tumour progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings suggest that 3D co-culture models offer an excellent system for studying the role of immune cells, specifically TAMs, in meningioma progression. By providing a more accurate representation of the TME, these models can help identify novel immunotherapy strategies aimed at modulating the immune response within meningiomas. Ultimately, this approach may improve therapeutic outcomes and quality of life for patients with meningioma by enhancing the effectiveness of existing treatments or by offering new immunotherapeutic options.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03419-2","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T02:31:07Z","timestamp":1748313067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumour-associated macrophage infiltration differs in meningioma genotypes, and is important in tumour dynamics"],"prefix":"10.1186","volume":"44","author":[{"given":"Ting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyorgy","family":"Fejer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Ercolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cutajar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Oliver","family":"Hanemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"3419_CR1","doi-asserted-by":"crossref","unstructured":"Ogasawara C, Philbrick BD, Adamson DC, Meningioma. A review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines. 2021;9(3).","DOI":"10.3390\/biomedicines9030319"},{"issue":"8","key":"3419_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"6","key":"3419_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s13311-022-01249-0","volume":"19","author":"HL Smith","year":"2022","unstructured":"Smith HL, Wadhwani N, Horbinski C. Major features of the 2021 WHO classification of CNS tumors. Neurotherapeutics. 2022;19(6):1691\u2013704.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"3419_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10143-023-02128-8","volume":"46","author":"R Costanzo","year":"2023","unstructured":"Costanzo R, Simonetta I, Musso S, Benigno UE, Cusimano LM, Giovannini EA, et al. Role of mediterranean diet in the development and recurrence of meningiomas: a narrative review. Neurosurg Rev. 2023;46(1):255.","journal-title":"Neurosurg Rev"},{"issue":"Suppl 1","key":"3419_CR5","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/neuonc\/noy178","volume":"21","author":"S Suppiah","year":"2019","unstructured":"Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, et al. Molecular and translational advances in meningiomas. Neuro Oncol. 2019;21(Suppl 1):i4\u201317.","journal-title":"Neuro Oncol"},{"issue":"10","key":"3419_CR6","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","volume":"26","author":"JZ Wang","year":"2024","unstructured":"Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, et al. Meningioma: international consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol. 2024;26(10):1742\u201380.","journal-title":"Neuro Oncol"},{"issue":"6123","key":"3419_CR7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077\u201380.","journal-title":"Science"},{"issue":"5","key":"3419_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682\u201394.","journal-title":"Lancet Oncol"},{"issue":"7874","key":"3419_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R, et al. A clinically applicable integrative molecular classification of meningiomas. Nature. 2021;597(7874):119\u201325.","journal-title":"Nature"},{"issue":"5","key":"3419_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA, et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet. 2022;54(5):649\u201359.","journal-title":"Nat Genet"},{"issue":"5","key":"3419_CR11","doi-asserted-by":"publisher","first-page":"eabm6247","DOI":"10.1126\/sciadv.abm6247","volume":"8","author":"CC Bayley JCt, Hadley","year":"2022","unstructured":"Bayley JCt, Hadley CC, Harmanci AO, Harmanci AS, Klisch TJ, Patel AJ. Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Sci Adv. 2022;8(5):eabm6247.","journal-title":"Sci Adv"},{"issue":"11","key":"3419_CR12","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821\u201334.","journal-title":"Neuro Oncol"},{"issue":"1","key":"3419_CR13","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","volume":"13","author":"PK Brastianos","year":"2022","unstructured":"Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, et al. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022;13(1):1325.","journal-title":"Nat Commun"},{"issue":"1","key":"3419_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/noab118","volume":"24","author":"WL Bi","year":"2022","unstructured":"Bi WL, Nayak L, Meredith DM, Driver J, Du Z, Hoffman S, et al. Activity of PD-1 Blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022;24(1):101\u201313.","journal-title":"Neuro Oncol"},{"key":"3419_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3389\/fneur.2020.00945","volume":"11","author":"T Garzon-Muvdi","year":"2020","unstructured":"Garzon-Muvdi T, Bailey DD, Pernik MN, Pan E. Basis for immunotherapy for treatment of meningiomas. Front Neurol. 2020;11:945.","journal-title":"Front Neurol"},{"key":"3419_CR16","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3419_CR17","first-page":"vdz018","volume":"1","author":"DT Proctor","year":"2019","unstructured":"Proctor DT, Huang J, Lama S, Albakr A, Van Marle G, Sutherland GR. Tumor-associated macrophage infiltration in meningioma. Neurooncol Adv. 2019;1(1):vdz018.","journal-title":"Neurooncol Adv"},{"key":"3419_CR18","doi-asserted-by":"crossref","unstructured":"Chen X, Tian F, Lun P, Feng Y. Profiles of immune infiltration and its relevance to survival outcome in meningiomas. Biosci Rep. 2020;40(5).","DOI":"10.1042\/BSR20200538"},{"key":"3419_CR19","doi-asserted-by":"crossref","unstructured":"Borch JS, Haslund-Vinding J, Vilhardt F, Maier AD, Mathiesen T. Meningioma-Brain crosstalk: A scoping review. Cancers (Basel). 2021;13(17).","DOI":"10.3390\/cancers13174267"},{"issue":"4","key":"3419_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/0394632017730241","volume":"30","author":"I Presta","year":"2017","unstructured":"Presta I, Guadagno E, Di Vito A, Malara N, Mignogna C, Maisano D, et al. Innate immunity May play a role in growth and relapse of chordoid meningioma. Int J Immunopathol Pharmacol. 2017;30(4):429\u201333.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"3419_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cell.2019.08.053","volume":"179","author":"M Prinz","year":"2019","unstructured":"Prinz M, Jung S, Priller J. Microglia biology: one century of evolving concepts. Cell. 2019;179(2):292\u2013311.","journal-title":"Cell"},{"key":"3419_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fncel.2018.00235","volume":"12","author":"D Matias","year":"2018","unstructured":"Matias D, Bal\u00e7a-Silva J, da Gra\u00e7a GC, Wanjiru CM, Macharia LW, Nascimento CP, et al. Microglia\/Astrocytes-Glioblastoma crosstalk: crucial molecular mechanisms and microenvironmental factors. Front Cell Neurosci. 2018;12:235.","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"3419_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10143-021-01642-x","volume":"45","author":"J Haslund-Vinding","year":"2022","unstructured":"Haslund-Vinding J, M\u00f8ller JR, Ziebell M, Vilhardt F, Mathiesen T. The role of systemic inflammatory cells in meningiomas. Neurosurg Rev. 2022;45(2):1205\u201315.","journal-title":"Neurosurg Rev"},{"issue":"6","key":"3419_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-019-02342-8","volume":"68","author":"YD Li","year":"2019","unstructured":"Li YD, Veliceasa D, Lamano JB, Lamano JB, Kaur G, Biyashev D, et al. Systemic and local immunosuppression in patients with high-grade meningiomas. Cancer Immunol Immunother. 2019;68(6):999\u20131009.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"3419_CR25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/neuonc\/not110","volume":"15","author":"L Fang","year":"2013","unstructured":"Fang L, Lowther DE, Meizlish ML, Anderson RC, Bruce JN, Devine L, et al. The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol. 2013;15(11):1479\u201390.","journal-title":"Neuro Oncol"},{"issue":"1","key":"3419_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s40478-023-01677-9","volume":"11","author":"LL van de Weijer","year":"2023","unstructured":"van de Weijer LL, Ercolano E, Zhang T, Shah M, Banton MC, Na J, et al. A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomas. Acta Neuropathol Commun. 2023;11(1):198.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"3419_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40291-020-00462-x","volume":"24","author":"V Pestinger","year":"2020","unstructured":"Pestinger V, Smith M, Sillo T, Findlay JM, Laes JF, Martin G, et al. Use of an integrated Pan-Cancer oncology enrichment Next-Generation sequencing assay to measure tumour mutational burden and detect clinically actionable variants. Mol Diagn Ther. 2020;24(3):339\u201349.","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"3419_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bioinformatics\/btx536","volume":"34","author":"MF Rogers","year":"2018","unstructured":"Rogers MF, Shihab HA, Mort M, Cooper DN, Gaunt TR, Campbell C. FATHMM-XF: accurate prediction of pathogenic point mutations via extended features. Bioinformatics. 2018;34(3):511\u20133.","journal-title":"Bioinformatics"},{"issue":"1","key":"3419_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.20892\/j.issn.2095-3941.2016.0004","volume":"13","author":"SP Strom","year":"2016","unstructured":"Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med. 2016;13(1):3\u201311.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"3419_CR30","doi-asserted-by":"publisher","first-page":"11640","DOI":"10.1038\/s41598-021-91142-1","volume":"11","author":"YH Yan","year":"2021","unstructured":"Yan YH, Chen SX, Cheng LY, Rodriguez AY, Tang R, Cabrera K, et al. Confirming putative variants at \u2264\u20095% allele frequency using allele enrichment and Sanger sequencing. Sci Rep. 2021;11(1):11640.","journal-title":"Sci Rep"},{"issue":"2","key":"3419_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3747\/co.20.1449","volume":"20","author":"WD Foulkes","year":"2013","unstructured":"Foulkes WD, Real FX. Many mosaic mutations. Curr Oncol. 2013;20(2):85\u20137.","journal-title":"Curr Oncol"},{"issue":"3","key":"3419_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.cels.2015.08.015","volume":"1","author":"M Griffith","year":"2015","unstructured":"Griffith M, Miller CA, Griffith OL, Krysiak K, Skidmore ZL, Ramu A, et al. Optimizing cancer genome sequencing and analysis. Cell Syst. 2015;1(3):210\u201323.","journal-title":"Cell Syst"},{"key":"3419_CR33","doi-asserted-by":"crossref","unstructured":"Adams CL, Ercolano E, Ferluga S, Sofela A, Dave F, Negroni C et al. A rapid robust method for subgrouping Non-NF2 meningiomas according to genotype and detection of lower levels of M2 macrophages in AKT1 E17K mutated tumours. Int J Mol Sci. 2020;21(4).","DOI":"10.3390\/ijms21041273"},{"issue":"7697","key":"3419_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469\u201374.","journal-title":"Nature"},{"issue":"3","key":"3419_CR35","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jmoldx.2015.11.009","volume":"18","author":"P Bady","year":"2016","unstructured":"Bady P, Delorenzi M, Hegi ME. Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors. J Mol Diagn. 2016;18(3):350\u201361.","journal-title":"J Mol Diagn"},{"issue":"1","key":"3419_CR36","first-page":"vdab031","volume":"3","author":"Z Woolf","year":"2021","unstructured":"Woolf Z, Swanson MEV, Smyth LC, Mee EW, Schweder P, Heppner P, et al. Single-cell image analysis reveals a protective role for microglia in glioblastoma. Neurooncol Adv. 2021;3(1):vdab031.","journal-title":"Neurooncol Adv"},{"key":"3419_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fncel.2020.00198","volume":"14","author":"AM Jurga","year":"2020","unstructured":"Jurga AM, Paleczna M, Kuter KZ. Overview of general and discriminating markers of differential microglia phenotypes. Front Cell Neurosci. 2020;14:198.","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"3419_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41582-021-00463-2","volume":"17","author":"L Keane","year":"2021","unstructured":"Keane L, Cheray M, Blomgren K, Joseph B. Multifaceted microglia - key players in primary brain tumour heterogeneity. Nat Rev Neurol. 2021;17(4):243\u201359.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"3419_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"key":"3419_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ebiom.2018.12.048","volume":"40","author":"J Dunn","year":"2019","unstructured":"Dunn J, Ferluga S, Sharma V, Futschik M, Hilton DA, Adams CL, et al. Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine. 2019;40:77\u201391.","journal-title":"EBioMedicine"},{"key":"3419_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/7651_2014_99","volume":"1304","author":"C Riedhammer","year":"2016","unstructured":"Riedhammer C, Halbritter D, Weissert R. Peripheral blood mononuclear cells: isolation, freezing, thawing, and culture. Methods Mol Biol. 2016;1304:53\u201361.","journal-title":"Methods Mol Biol"},{"key":"3419_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.diff.2022.10.001","volume":"128","author":"ZN Mohd Yasin","year":"2022","unstructured":"Mohd Yasin ZN, Mohd Idrus FN, Hoe CH, Yvonne-Tee GB. Macrophage polarization in THP-1 cell line and primary monocytes: A systematic review. Differentiation. 2022;128:67\u201382.","journal-title":"Differentiation"},{"issue":"4","key":"3419_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"11","key":"3419_CR44","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood.2021015024","volume":"139","author":"Z Li","year":"2022","unstructured":"Li Z, Murphy PM. CD45: a niche marker for allotransplantation. Blood. 2022;139(11):1614\u20136.","journal-title":"Blood"},{"key":"3419_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.biomaterials.2017.11.028","volume":"156","author":"S Zhang","year":"2018","unstructured":"Zhang S, Chuah SJ, Lai RC, Hui JHP, Lim SK, Toh WS. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials. 2018;156:16\u201327.","journal-title":"Biomaterials"},{"issue":"1","key":"3419_CR46","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1038\/s41467-022-30757-y","volume":"13","author":"S Lin","year":"2022","unstructured":"Lin S, Zhang A, Yuan L, Wang Y, Zhang C, Jiang J, et al. Targeting parvalbumin promotes M2 macrophage polarization and energy expenditure in mice. Nat Commun. 2022;13(1):3301.","journal-title":"Nat Commun"},{"key":"3419_CR47","doi-asserted-by":"publisher","first-page":"902372","DOI":"10.3389\/fncel.2022.902372","volume":"16","author":"C Ruan","year":"2022","unstructured":"Ruan C, Elyaman W. A new Understanding of TMEM119 as a marker of microglia. Front Cell Neurosci. 2022;16:902372.","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"3419_CR48","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00018-011-0848-6","volume":"69","author":"RC Ji","year":"2012","unstructured":"Ji RC. Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis. Cell Mol Life Sci. 2012;69(6):897\u2013914.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"3419_CR49","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/jop.12643","volume":"47","author":"AM Alves","year":"2018","unstructured":"Alves AM, Diel LF, Lamers ML. Macrophages and prognosis of oral squamous cell carcinoma: A systematic review. J Oral Pathol Med. 2018;47(5):460\u20137.","journal-title":"J Oral Pathol Med"},{"key":"3419_CR50","doi-asserted-by":"crossref","unstructured":"G\u00f3mez Morillas A, Besson VC, Lerouet D. Microglia and neuroinflammation: what place for P2RY12? Int J Mol Sci. 2021;22(4).","DOI":"10.3390\/ijms22041636"},{"key":"3419_CR51","doi-asserted-by":"crossref","unstructured":"Dave F, Herrera K, Lockley A, van de Weijer LL, Henderson S, Sofela AA et al. Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and Schwannoma tumours. Oncogene. 2024.","DOI":"10.1038\/s41388-024-03177-z"},{"key":"3419_CR52","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-3-031-29750-2_14","volume":"1416","author":"JZ Wang","year":"2023","unstructured":"Wang JZ, Nassiri F, Bi L, Zadeh G. Immune profiling of meningiomas. Adv Exp Med Biol. 2023;1416:189\u201398.","journal-title":"Adv Exp Med Biol"},{"issue":"34","key":"3419_CR53","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.21.00784","volume":"39","author":"SLN Maas","year":"2021","unstructured":"Maas SLN, Stichel D, Hielscher T, Sievers P, Berghoff AS, Schrimpf D, et al. Integrated Molecular-Morphologic meningioma classification: A multicenter retrospective analysis, retrospectively and prospectively validated. J Clin Oncol. 2021;39(34):3839\u201352.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3419_CR54","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/jnen\/nlaa152","volume":"80","author":"J Yeung","year":"2021","unstructured":"Yeung J, Yaghoobi V, Aung TN, Vesely MD, Zhang T, Gaule P, et al. Spatially resolved and quantitative analysis of the immunological landscape in human meningiomas. J Neuropathol Exp Neurol. 2021;80(2):150\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3419_CR55","doi-asserted-by":"crossref","unstructured":"Lotsch C, Warta R, Herold-Mende C. The molecular and immunological landscape of meningiomas. Int J Mol Sci. 2024;25(17).","DOI":"10.3390\/ijms25179631"},{"issue":"4","key":"3419_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.pathol.2021.10.002","volume":"54","author":"CP Turner","year":"2022","unstructured":"Turner CP, McLay J, Hermans IF, Correia J, Bok A, Mehrabi N, et al. Tumour infiltrating lymphocyte density differs by meningioma type and is associated with prognosis in atypical meningioma. Pathology. 2022;54(4):417\u201324.","journal-title":"Pathology"},{"issue":"17","key":"3419_CR57","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-19-0389","volume":"25","author":"C Rapp","year":"2019","unstructured":"Rapp C, Dettling S, Liu F, Ull AT, Warta R, Jungk C, et al. Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas. Clin Cancer Res. 2019;25(17):5260\u201370.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3419_CR58","doi-asserted-by":"publisher","first-page":"e12970","DOI":"10.1111\/bpa.12970","volume":"32","author":"AS Berghoff","year":"2022","unstructured":"Berghoff AS, Hielscher T, Ricken G, Furtner J, Schrimpf D, Widhalm G, et al. Prognostic impact of genetic alterations and methylation classes in meningioma. Brain Pathol. 2022;32(2):e12970.","journal-title":"Brain Pathol"},{"key":"3419_CR59","doi-asserted-by":"crossref","unstructured":"Szulzewsky F, Thirimanne HN, Holland EC. Meningioma: current updates on genetics, classification, and mouse modeling. Ups J Med Sci. 2024;129.","DOI":"10.48101\/ujms.v129.10579"},{"key":"3419_CR60","doi-asserted-by":"crossref","unstructured":"Ochocka N, Kaminska B. Microglia diversity in healthy and diseased brain: insights from Single-Cell omics. Int J Mol Sci. 2021;22(6).","DOI":"10.3390\/ijms22063027"},{"key":"3419_CR61","doi-asserted-by":"crossref","unstructured":"Miller TE, El Farran CA, Couturier CP, Chen Z, D\u2019Antonio JP, Verga J et al. Programs, origins and Immunomodulatory functions of myeloid cells in glioma. Nature. 2025.","DOI":"10.1038\/s41586-025-08633-8"},{"issue":"1","key":"3419_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.tcb.2016.08.003","volume":"27","author":"AQ Kohrman","year":"2017","unstructured":"Kohrman AQ, Matus DQ. Divide or conquer: cell cycle regulation of invasive behavior. Trends Cell Biol. 2017;27(1):12\u201325.","journal-title":"Trends Cell Biol"},{"issue":"12","key":"3419_CR63","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"3419_CR64","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"3419_CR65","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553\u201372.","journal-title":"Tumour Biol"},{"issue":"3","key":"3419_CR66","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00401-022-02455-y","volume":"144","author":"HN Vasudevan","year":"2022","unstructured":"Vasudevan HN, Choudhury A, Hilz S, Villanueva-Meyer JE, Chen WC, Lucas CG, et al. Intratumor and informatic heterogeneity influence meningioma molecular classification. Acta Neuropathol. 2022;144(3):579\u201383.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"3419_CR67","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1038\/s41467-020-18582-7","volume":"11","author":"ST Magill","year":"2020","unstructured":"Magill ST, Vasudevan HN, Seo K, Villanueva-Meyer JE, Choudhury A, John Liu S, et al. Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat Commun. 2020;11(1):4803.","journal-title":"Nat Commun"},{"issue":"5","key":"3419_CR68","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/cts.13066","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Brown PC, Chow ECY, Ewart L, Ferguson SS, Fitzpatrick S, et al. 3D cell culture models: drug pharmacokinetics, safety assessment, and regulatory consideration. Clin Transl Sci. 2021;14(5):1659\u201380.","journal-title":"Clin Transl Sci"},{"key":"3419_CR69","doi-asserted-by":"crossref","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization States in the tumor microenvironment. Int J Mol Sci. 2021;22(13).","DOI":"10.3390\/ijms22136995"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03419-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03419-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03419-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:02:56Z","timestamp":1748318576000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03419-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3419"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03419-2","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients prior to sample collection. All specimens were acquired through the Plymouth Brain Tumour Biobank (REC No: 24\/SC\/0278; IRAS No: 345630) with approval from the ethics committee at University Hospitals Plymouth NHS Trust and North Bristol NHS Trust. Ten additional samples were provided by the Department of Neuropathology Biobank at Heidelberg University Hospital, Germany (Ethics Approval No: S-318\/2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}